Vaccine production, distribution, access, and uptake

[1]  M. Lipsitch,et al.  Serotype replacement in disease following pneumococcal vaccination : A discussion of the evidence , 2012 .

[2]  M. Lipsitch,et al.  Serotype replacement in disease after pneumococcal vaccination , 2011, The Lancet.

[3]  T. Cherian,et al.  The future of immunisation policy, implementation, and financing , 2011, The Lancet.

[4]  E. Moxon,et al.  The next decade of vaccines: societal and scientific challenges , 2011, The Lancet.

[5]  Nikolai Petrovsky,et al.  The Vaccine Renaissance , 2011, Human vaccines.

[6]  R. Compans,et al.  Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus , 2010, Proceedings of the National Academy of Sciences.

[7]  Paul Farmer,et al.  Five complementary interventions to slow cholera: Haiti , 2010, The Lancet.

[8]  P. Hotez,et al.  A national cholera vaccine stockpile--a new humanitarian and diplomatic resource. , 2010, The New England journal of medicine.

[9]  A. Fauci,et al.  Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine , 2010, Nature Medicine.

[10]  D. Ekiert,et al.  Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes , 2010, Proceedings of the National Academy of Sciences.

[11]  R. Brookmeyer,et al.  H1N1pdm in the Americas. , 2010, Epidemics.

[12]  John F. Modlin,et al.  The bumpy road to polio eradication. , 2010, The New England journal of medicine.

[13]  L. Vézina,et al.  The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. , 2010, Plant biotechnology journal.

[14]  David P. Fidler,et al.  Negotiating Equitable Access to Influenza Vaccines: Global Health Diplomacy and the Controversies Surrounding Avian Influenza H5N1 and Pandemic Influenza H1N1 , 2010, PLoS medicine.

[15]  R. Rappuoli,et al.  Universal Vaccines: Shifting to One for Many , 2010, mBio.

[16]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[17]  D. Earn,et al.  Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. , 2010, JAMA.

[18]  J Wallinga,et al.  Distribution of vaccine/antivirals and the ‘least spread line’ in a stratified population , 2010, Journal of The Royal Society Interface.

[19]  M. van Boven,et al.  Optimizing infectious disease interventions during an emerging epidemic , 2009, Proceedings of the National Academy of Sciences.

[20]  Kosa Sudhorm,et al.  Pandemic (H1N1) 2009 , 2009 .

[21]  A. Kamen,et al.  Development of a simple and high-yielding fed-batch process for the production of influenza vaccines. , 2009, Vaccine.

[22]  J. Kahn,et al.  HPV vaccination for the prevention of cervical intraepithelial neoplasia. , 2009, The New England journal of medicine.

[23]  M. Pagano,et al.  Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA , 2009, Influenza and other respiratory viruses.

[24]  J Wallinga,et al.  Reproductive numbers, epidemic spread and control in a community of households. , 2009, Mathematical biosciences.

[25]  E. Lyons,et al.  Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings , 2009, Science.

[26]  M. Safan,et al.  Transmission potential of the new influenza A(H1N1) virus and its age-specificity in Japan. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[27]  D. Jacobson,et al.  Vaccine production in Neurospora crassa. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[28]  S. Halperin,et al.  Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis Vaccines) , 2009, Expert review of vaccines.

[29]  R. Schwartz,et al.  Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. , 2009, Vaccine.

[30]  M. Howard,et al.  Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines , 2009, Expert review of vaccines.

[31]  M. Havenga,et al.  Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. , 2009, Vaccine.

[32]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[33]  Lynnette Brammer,et al.  Estimates of US influenza‐associated deaths made using four different methods , 2009, Influenza and other respiratory viruses.

[34]  R. Mikolajczyk,et al.  Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases , 2008, PLoS medicine.

[35]  Cécile Viboud,et al.  Epidemiologic characterization of the 1918 influenza pandemic summer wave in Copenhagen: implications for pandemic control strategies. , 2008, The Journal of infectious diseases.

[36]  R. Hutubessy,et al.  Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. , 2008, Bulletin of the World Health Organization.

[37]  Cecile Viboud,et al.  Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. , 2007, The Lancet. Infectious diseases.

[38]  C. Fraser.  Estimating Individual and Household Reproduction Numbers in an Emerging Epidemic , 2007, PloS one.

[39]  Cecile Viboud,et al.  Vaccinating to Protect a Vulnerable Subpopulation , 2007, PLoS medicine.

[40]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[41]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. McNeil.  Who invented the VLP cervical cancer vaccines? , 2006, Journal of the National Cancer Institute.

[43]  Susan Partridge,et al.  Efficacy of an acellular pertussis vaccine among adolescents and adults. , 2005, The New England journal of medicine.

[44]  H. Keyserling,et al.  Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. , 2005, Archives of pediatrics & adolescent medicine.

[45]  D. Cummings,et al.  Strategies for containing an emerging influenza pandemic in Southeast Asia , 2005, Nature.

[46]  D. Fedson.  Preparing for Pandemic Vaccination: An International Policy Agenda for Vaccine Development , 2005, Journal of public health policy.

[47]  M Elizabeth Halloran,et al.  Strategy for distribution of influenza vaccine to high-risk groups and children. , 2005, American journal of epidemiology.

[48]  J. Robins,et al.  Transmissibility of 1918 pandemic influenza , 2004, Nature.

[49]  S. Dowell,et al.  Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis , 2000, Pediatrics.

[50]  M. Lipsitch.  Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. , 1999, Emerging infectious diseases.

[51]  L. Simonsen,et al.  Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. , 1998, The Journal of infectious diseases.

[52]  W. C. Gamble,et al.  Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. , 1995, Vaccine.

[53]  S. Larsen,et al.  Epidemiology of pertussis in Denmark: the impact of herd immunity. , 1994, International Journal of Epidemiology.

[54]  P. Kaye.  Infectious diseases of humans: Dynamics and control , 1993 .

[55]  J. Menitove.  Research and Development Programs , 1992 .